The authors evaluated the efficacy of C225 mAbs to target EGFR and improve the internalization, the chemical sensitivity of the cancer cells, and the efficacy of the gold nanoparticles, using different types of EGFR-expressing NSCLC cancer cell lines. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.